Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Foghorn Therapeutics raises $50m in funding
Foghorn initially commenced operations in 2016, and developed a Gene Traffic Control product platform to discover and develop drugs based on insights into the chromatin regulatory system that
Foghorn initially commenced operations in 2016, and developed a Gene Traffic Control product platform to discover and develop drugs based on insights into the chromatin regulatory system that
The trial was evaluating the safety and efficacy of the investigational therapy in ambulatory and non-ambulatory children and adolescents with the genetic disorder. According to Solid Biosciences, the
The company’s supplemental Biologics License Application (sBLA), which has been accepted by the regulator, is seeking approval for treating patients whose cervical cancer had progressed on or after
In May 2017, the FDA turned down VR315, a generic version of GlaxoSmithKline’s asthma/COPD inhaler Advair Diskus. During that time, the companies received a complete response letter from the FDA.
PF-04958242, which is ready for phase 2b development, is an AMPA receptor potentiator, developed for treating cognitive impairment associated with schizophrenia (CIAS). AMPA receptors restore excitatory synaptic transmission process
The Odyssey Outcomes trial, which met its primary endpoint, was held in nearly 19,000 patients who had a recent acute coronary syndrome (ACS) event, such as a heart
Tofacitinib is a Janus kinase (JAK) inhibitor, which is yet to secure approval for the treatment of UC. The FDA and the European Medicines Agency (EMA) are currently reviewing the
The platform will be led by Evotec for which Sanofi will license more than ten of its infectious disease research and early-stage development portfolio. Evotec will run the
Lenvima is an orally available tyrosine kinase inhibitor discovered by Eisai. The partnership will jointly develop and commercialize Lenvima as monotherapy and in combination with Merck’s anti-PD-1 therapy
The Pharma giant expanded alliance with Science 37 to advance virtual clinical trials program. The trials will be a mix of virtual and traditional models and will have increasing